Miami, FL (May 19, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin™ to hospitals and clinics in the country. [Read more…]
What are Exosomes, Exactly?
What are exosomes? For many years, exosomes were considered to be transporters of cellular waste, but they are now recognized for their essential role in intercellular communication and transportation.
[Read more…]
The Booming Market for Exosomes in 2021
Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection. [Read more…]
Organicell Receives Approval In Pakistan For The Use Of Zofin™ For Compassionate Grounds For COVID-19
Clinical Trials To Commence Immediately
Miami, FL (May 11, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani regulators to be used for a COVID-19 patient on compassionate grounds. [Read more…]
Organicell Announces Positive Results Of Initial COVID-19 Zofin™ Patient Trial In India And Trial Expansion
Miami, FL (April 28, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell’s Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients. [Read more…]
